Optinose Us Inc Drug Patent Portfolio
Optinose Us Inc owns 1 orange book drug protected by 20 US patents Given below is the list of Optinose Us Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11554229 | Nasal administration | 23 Feb, 2036 | Active |
| US10300229 | Nasal delivery devices | 07 Jul, 2035 | Active |
| US10076614 | Nasal delivery devices | 20 Oct, 2034 | Active |
| US10478574 | Nasal administration | 04 Nov, 2033 | Active |
| US10179216 | Nasal delivery devices | 08 Jul, 2033 | Active |
| US11033696 | Nasal delivery devices | 20 May, 2033 | Active |
| US12083270 | Delivery device and method | 04 Apr, 2031 | Active |
| US10252010 | Nasal delivery devices | 07 Feb, 2031 | Active |
| US8978647 | Nasal delivery | 06 Dec, 2030 | Active |
| US8550073 | Nasal delivery | 22 Oct, 2029 | Active |
| US10076615 | Nasal delivery | 30 Jul, 2029 | Active |
| US11602603 | Nasal delivery devices | 27 Oct, 2028 | Active |
| US10124132 | Nasal delivery | 06 Mar, 2027 | Active |
| US7975690 | Nasal devices | 29 Dec, 2025 | Active |
| US8522778 | Nasal devices | 20 Apr, 2024 | Expired |
| US8327844 | Nasal delivery method | 24 Oct, 2023 | Expired |
| US9072857 | Nasal delivery device | 10 Apr, 2021 | Expired |
| US6715485 | Nasal delivery device | 03 Sep, 2020 | Expired |
| US9468727 | Nasal delivery | 30 Jul, 2020 | Expired |
| US8555878 | Nasal delivery device | 20 Mar, 2020 | Expired |
Latest Legal Activities on Optinose Us Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Optinose Us Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US9468727 |
|
Expire Patent
Critical
| 14 Aug, 2023 | US9072857 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Mar, 2023 | US11602603 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Mar, 2023 | US11602603 |
|
Maintenance Fee Reminder Mailed
Critical
| 27 Feb, 2023 | US9072857 |
|
Email Notification
Critical
| 23 Feb, 2023 | US11602603 |
|
Issue Notification Mailed
Critical
| 22 Feb, 2023 | US11602603 |
|
Application Is Considered Ready for Issue
Critical
| 15 Feb, 2023 | US11602603 |
| Dispatch to FDC | 15 Feb, 2023 | US11602603 |
|
Issue Fee Payment Verified
Critical
| 14 Feb, 2023 | US11602603 |
|
Issue Fee Payment Received
Critical
| 14 Feb, 2023 | US11602603 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Jan, 2023 | US11554229 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Jan, 2023 | US11554229 |
|
Email Notification
Critical
| 29 Dec, 2022 | US11554229 |
|
Issue Notification Mailed
Critical
| 28 Dec, 2022 | US11554229 |
Optinose Us Inc Drug Patents' Oppositions Filed in EPO
Optinose Us Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17190469A | Aug, 2021 | Beck Greener LLP | Granted and Under Opposition |
| EP08736896A | Jun, 2021 | Beck Greener LLP | Patent maintained as amended |
| EP13715145A | Sep, 2020 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP00906570A | Sep, 2005 | Direct-Haler A/S | Opposition rejected |
Optinose Us Inc's Family Patents
Optinose Us Inc drugs have patent protection in a total of 30 countries. It's US patent count contributes only to 19.2% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Optinose Us Inc Drug List
Given below is the complete list of Optinose Us Inc's drugs and the patents protecting them.
1. Xhance
Xhance is protected by 20 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11554229 | Nasal administration |
23 Feb, 2036
(11 years from now)
| Active |
| US10300229 | Nasal delivery devices |
07 Jul, 2035
(10 years from now)
| Active |
| US10076614 | Nasal delivery devices |
20 Oct, 2034
(9 years from now)
| Active |
| US10478574 | Nasal administration |
04 Nov, 2033
(8 years from now)
| Active |
| US10179216 | Nasal delivery devices |
08 Jul, 2033
(8 years from now)
| Active |
| US11033696 | Nasal delivery devices |
20 May, 2033
(8 years from now)
| Active |
| US12083270 | Delivery device and method |
04 Apr, 2031
(6 years from now)
| Active |
| US10252010 | Nasal delivery devices |
07 Feb, 2031
(6 years from now)
| Active |
| US8978647 | Nasal delivery |
06 Dec, 2030
(5 years from now)
| Active |
| US8550073 | Nasal delivery |
22 Oct, 2029
(4 years from now)
| Active |
| US10076615 | Nasal delivery |
30 Jul, 2029
(4 years from now)
| Active |
| US11602603 | Nasal delivery devices |
27 Oct, 2028
(3 years from now)
| Active |
| US10124132 | Nasal delivery |
06 Mar, 2027
(2 years from now)
| Active |
| US7975690 | Nasal devices |
29 Dec, 2025
(1 year, 10 days from now)
| Active |
| US8522778 | Nasal devices |
20 Apr, 2024
(7 months ago)
| Expired |
| US8327844 | Nasal delivery method |
24 Oct, 2023
(1 year, 1 month ago)
| Expired |
| US9072857 | Nasal delivery device |
10 Apr, 2021
(3 years ago)
| Expired |
| US6715485 | Nasal delivery device |
03 Sep, 2020
(4 years ago)
| Expired |
| US9468727 | Nasal delivery |
30 Jul, 2020
(4 years ago)
| Expired |
| US8555878 | Nasal delivery device |
20 Mar, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xhance's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List